- Proprietary Technology Strengthens Patent Portfolio -

Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Canadian Intellectual Property Office that it has obtained patent issuance for its proprietary drug, Soluble Ferric Pyrophosphate (SFP), the Company's late-stage investigational drug that provides iron replacement to hemodialysis patients with CKD. The Canadian patent grant covers the method and pharmaceutical composition for SFP-iron delivery in hemodialysis and peritoneal dialysis patients.

Mr. Robert L. Chioini, Chairman and CEO of Rockwell stated, "We are pleased to secure patent protection for SFP-iron delivery in an important market such as Canada. In conjunction with the successful completion of our SFP clinical studies, we will continue to evaluate worldwide market opportunities with an established marketing partner for the development and distribution of SFP."

About Rockwell Medical:

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. Rockwell's lead, late-stage investigational drug for iron therapy treatment is called SFP. SFP delivers iron in a non-invasive, physiologic manner to dialysis patients via dialysate during their regular dialysis treatment. SFP is currently in ongoing Phase III clinical trials (CRUISE-1 and CRUISE-2) and addresses a $600M U.S. and $1B global market. Rockwell's Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism addresses a $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. These products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell's operating business is designed as a ready-made sales and distribution channel to provide seamless integration into the commercial market for its drug products, Calcitriol and SFP upon FDA market approval.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of SFP's unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and SFP following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Michael Rice
Investor Relations
(646) 597-6979

...

New dialysis unit will be built at Withybush Hospital

1:08pm Wednesday 27th June 2012 in News

Withybush Hospital will have a new Renal Dialysis Unit despite concerns earlier this year that the unit would never be built.

Welsh Government Health Minister Lesley Griffiths has announced that a £7.5million upgrade will go ahead with construction beginning before the end of the summer.

In April the Renal Network UK pulled out of plans to build a 21 station state-of-the-art renal unit at Withybush Hospital citing cost of altering the road infrastructure and car park.

Mrs Griffiths announced yesterday (Tuesday) that the 21 station unit will go ahead within the hospital grounds meaning more patients will have the opportunity to undergo treatment locally.

The Renal Dialysis Unit currently operates in a temporary building housing only six stations. Although it has been designed to facilitate haemodialysis, it was only intended for use as an interim facility.

The new unit will deliver vital renal services for the patients of West Wales, providing environmental and patient focussed designs required of modern renal unit.

Building will start on site in August 2012 and could be complete by early 2014.

Mrs Griffiths said: “I am delighted to announce this funding. The number of patients relying on dialysis continues to increase and this unit will be ideally placed to accommodate the growth in demand.

“At a time of such perceived uncertainty, this demonstrates the Welsh Government is committed to improving services in Wales to make them safe and sustainable for now and into the future.”

The announcement was welcomed by Mid and West Wales AMs Joyce Watson and Rebecca Evans.

Mrs Watson said: “My husband Wally used to install dialysis facilities when he worked for the NHS – I know how much it affects people’s lives. Having a permanent unit so close to home will have a huge benefit in terms of patients’ quality of life.

“It is exactly what Pembrokeshire’s dialysis patients and their families have called for – a permanent home for renal care at Withybush.

“Patients that I spoke to argued that building the unit at Withybush, with access to proper medical care, was absolutely crucial for both their safety and their peace of mind. So I am delighted by the Minister’s ongoing commitment to this project and to Withybush Hospital.”

Comments(2)

power71 says...
4:41pm Wed 27 Jun 12

philipw says...
6:32pm Wed 27 Jun 12

Comment now! Register or sign in below.

Or

...